Canaccord raised the firm’s price target on Cardiol Therapeutics to $8 from $6 and keeps a Buy rating on the shares. The firm noted they reported financial results for 1Q24 without issuing a press release but the company announced that it has presented an abstract at the World Congress on Acute Heart Failure 2024 from the ongoing Phase II ARCHER trial in acute myocarditis.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRDL: